Cowen inc (COWN) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
(Lia Shaked)
Health technology company Carevive which developed a platform that helps clinicians create personalized treatment plans for cancer patients won a new major backer last month.
The company banked a series C equity investment of $18 million with support from Philips Health Technology Ventures. Phillips joined prior investors HLM Venture Partners, LRVHealth, Cerner and founder Madelyn Trupkin Herzfeld in the round.
Carevive s platform allows clinicians to tailor cancer care management programs for each patient s needs, informed by real-world patient experiences and outcomes, not just clinical data. Its remote symptom management system means patients need to take fewer trips to health centers. And Carevive s data and analytics are helping researchers design innovative cancer care delivery models, payers to reimburse treatments effectively and life science companies to develop personalized therapies for cancer.
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company s business during a fireside chat session at the 41st annual Cowen Health Care Conference.
The session will take place virtually on Wednesday March 3, 2021, from 10:20 a.m. to 10:50 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.
MedCity News
Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic
In the past year, Evox Therapeutics has inked alliances with two big pharma companies. The Series C financing now positions the biotech to advance to the clinic with its own exosome-based therapies.
Shares0
Cells in the body share material via tiny vesicles that shuttle between them, carrying molecular payloads from one cell to another. Evox Therapeutics is developing medicines that leverage this mechanism as way of accessing cells and tissues that are beyond the reach of current drug technologies.
The biotech has research partnerships with two large pharmaceutical companies. Now it has $95.4 million to advance into clinical testing with several rare disease drug candidates. Redmile Group led the Series C round of funding.
Share this article
Share this article
OXFORD, England, Feb. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round.
The financing was significantly oversubscribed with high demand from both existing and new investors. The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a $10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of this round.